



# Meningococcal Disease Quicksheet



## Infectious Agent

*Neisseria meningitidis*, a gram-negative diplococcus bacterium carried by 5-10% of the population.

## Clinical Description

Invasive disease manifests most commonly as meningitis and/or meningococemia and may progress to purpura fulminans, shock, and death within hours of onset. Other manifestations, such as septic arthritis or orbital cellulitis, may be observed. The case fatality rate is 10% and 11-19% of surviving patients have sequelae (e.g., neurologic disability, limb loss, and hearing loss).

## Mode of Transmission

Transmission occurs through contact with aerosols from the nose, throat, and mouth of colonized or infected persons. *N. meningitidis* may be carried in the nasopharynx of otherwise healthy individuals. Invasive meningococcal disease occurs primarily in individuals who are newly colonized with the organism, usually within the first few days.

## Incubation Period

From 1-10 days, usually less than 4 days.

## Period of Communicability

Persons with meningococcal disease are considered infectious 7 days before onset of disease until 24 hours after initiation of appropriate antibiotic therapy with the most infectious period shortly before symptom onset until initiation of antibiotic therapy.

## 2015 CDC/CSTE Case Definition

### Confirmed:

- Detection of *N. meningitidis*-specific nucleic acid in a specimen obtained from a normally sterile body site (e.g., blood or CSF), using a validated polymerase chain reaction (PCR) assay; or
- Isolation of *Neisseria meningitidis*
  - from a normally sterile body site (e.g., blood or cerebrospinal fluid, or, less commonly, synovial, pleural, or pericardial fluid), or
  - from purpuric lesions.

### Probable:

- Detection of *N. meningitidis* antigen in
  - formalin-fixed tissue by immunohistochemistry (IHC); or
  - in CSF by latex agglutination.

### Suspect:

- Clinical purpura fulminans in the absence of a positive blood culture; or
- Gram-negative diplococci, not yet identified, isolated from a normally sterile body site (e.g., blood or CSF).

## Culture-Negative Suspect Cases

If antibiotics have been given prior to specimen collection, sterile site cultures may be negative. In such cases, specimens may be submitted to the CDPH Microbial Diseases Laboratory (MDL) after collection, and PCR testing can be performed concurrently with cultures. In addition, specimens from culture-negative patients for whom there is strong suspicion of meningococcal disease can be submitted regardless of antibiotic history. See "[Laboratory Testing for Meningococcal Disease](https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/IMM-MeningLabTesting.pdf)" at: <https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/IMM-MeningLabTesting.pdf>

## Molecular Subtyping of Isolates

CDPH routinely submits *N. meningitidis* isolates to CDC for molecular subtyping. This information is extremely helpful in determining if a cluster or outbreak is occurring.

## Antimicrobial Resistance Testing

CDC has identified serogroup Y *N. meningitidis* isolates that are resistant to penicillin and ciprofloxacin in the U.S. in recent years, including a single California case in 2019. Clinicians should consider antimicrobial susceptibility testing (AST) on *N. meningitidis* isolates to inform treatment and post-exposure prophylaxis (PEP) decisions. AST should not delay initiation of PEP.

Although CDC conducts AST on *N. meningitidis* isolates submitted by CDPH, results are not available in a timely way and cannot be used for clinical or public health decision-making for individual cases.

### Case Investigation

- 1) Confirm that the suspected case meets the case definition and/or is highly suspected.
- 2) Identify and locate patient specimens. **Submit bacterial isolates or culture-negative sterile site specimens to CDPH MDL as soon as possible for serogrouping and additional testing.** See “Laboratory Testing for Meningococcal Disease”.
- 3) Empiric therapy for suspected meningococcal disease should include cefotaxime or ceftriaxone. Cases not treated with cefotaxime or ceftriaxone, which clear carriage, should receive chemoprophylaxis before hospital discharge (see page 3 for more information).
- 4) Identify all persons who had close contact with case within 7 days of case’s onset of symptoms until case has had 24 hours of effective antibiotic therapy (see definition of close contact below). To identify close contacts, interview the case, their household members and close friends as needed (for adolescents and young adults, close friends may be the only reliable source of information about contacts).
- 5) Regardless of the meningococcal vaccination status of the contact, recommend chemoprophylaxis for close contacts as soon as possible, ideally within 24 hours of identification of the index case and up to 14 days from the last exposure (see next page for information on expanded chemoprophylaxis).
- 6) For long-term protection, recommend meningococcal vaccines to unvaccinated close contacts and recovered cases with an ACIP recommendation for vaccination.
- 7) Meningococcal vaccine (MenACWY or MenB vaccines) may also be considered for unvaccinated:
  - o persons who are not close contacts but have an ACIP recommendation for vaccination to help reduce anxiety about exposure; and
  - o close contacts and recovered cases without an ACIP recommendation for vaccination (the risk of exposure may be longer than the very short period of protection from chemoprophylaxis, and cases may have an undiagnosed risk for meningococcal infection).

Children vaccinated before the age recommended by ACIP should receive additional dose(s) of vaccine at the recommended age(s).

- 8) Provide close contacts with information about the signs and symptoms of meningococcal disease and ask them to self-monitor for the onset of febrile illness.
- 9) Alert clinicians and educate the public, as indicated.
- 10) Recommend evaluation of previously immunized or recurrent cases for terminal complement or other immune deficiency; some experts recommend evaluation of all recovered cases.

### Close Contact Definition

Close contacts are people who may have been exposed to the respiratory aerosols of a case in the 7 days before the onset of symptoms in the case and until the case has had 24 hours of effective antimicrobial therapy. The following persons are considered close contacts:

- Household members.
- Childcare or preschool contacts.
- Persons with unprotected exposure to the case’s respiratory aerosols, e.g., via intubation, endotracheal tube management, suctioning, and mouth-to-mouth resuscitation.
- Persons who shared sleeping spaces with the case (e.g., dormitory, barracks).
- Persons with exposure to the index patient’s respiratory secretions through kissing or other markers of close or intimate contact (e.g., sharing toothbrushes, eating utensils or smoking materials). Although *N. meningitidis* is not commonly detected in saliva, these types of exposures are often used as indicators of close contact and aerosol exposure.
- Other persons who may be considered close contacts include those who are likely to have been exposed to aerosols or secretions from the case’s nose, throat, or mouth (e.g., close face-to-face contact, especially if prolonged).
- Per CDC, persons sitting directly next to the index case during airline flights lasting more than 8 hours.

When there are a large number of contacts or there is difficulty reaching contacts, priority should be given to persons with the most prolonged or intimate contact with the case, or contact with the case shortly before the onset of symptoms when cases are most infectious.

### Expanded Chemoprophylaxis

Offering chemoprophylaxis to those with casual or transient contact with the case is generally not recommended. However, in settings involving defined populations where it may be difficult to ascertain the individual degree of contact with the case, offering chemoprophylaxis to others beyond those identified as close contacts (expanded PEP) may be considered.

Examples include child care/kindergarten classrooms, small primary/secondary schools, jails, residential facilities, or defined social networks such as fraternity/sorority members, sports team members, and party attendees). Expanded PEP is often warranted for those in the social networks of college student cases.

If expanded PEP is undertaken, it should be administered to all targeted persons at the same time, ideally within 24 hours. Contact CDPH for consultation if expanded PEP is being considered.

### Outbreak Management and Mass Vaccination

An outbreak threshold is determined on a case-by-case basis but is generally defined as 1) 2-3 outbreak-associated cases within an organization during a 3-month period or 2) multiple outbreak-associated cases resulting in increased meningococcal disease incidence in a community during a 3-month period. If an outbreak is suspected, efforts should be made to ensure that isolates are submitted to public health laboratories for whole genome sequencing (WGS). Additional epidemiologic data should be collected from suspected cases to identify a possible risk group/network.

Vaccination is the preferred control measure for outbreaks of all serogroups commonly seen in the U.S., however mass vaccination decisions should be made on a case-by-case basis in consultation with CDPH, taking in account all circumstances and epidemiology specific to the outbreak. The vaccine used should reflect the outbreak serogroup.

### Licensed Meningococcal Vaccines

| Formulation¶ | Trade name | Licensed ages* | Serogroups |
|--------------|------------|----------------|------------|
| MenACWY-D    | Menactra®  | 9m-55y         | A, C, W, Y |
| MenACWY-CRM  | Menveo®    | 2m-55y         | A, C, W, Y |
| MenB-FHbp§   | Trumenba®  | 10-25y         | B          |
| MenB-4C      | Bexsero®   | 10-25y         | B          |

\*ACIP recommends the use of MenACWY vaccines in persons ≥56 years of age and MenB vaccines in persons ≥10 years of age who are at increased risk during an outbreak.

¶There is no brand preference, however for MenB vaccines, the same brand should be used for all doses in a series.

§If Trumenba® is used for a MenB outbreak response, ACIP recommends that the 3-dose series (0, 1-2, 6m) be used in order to provide earlier protection and maximize the immune response.

It takes ~2 weeks after vaccination for the development of protective antibody levels. Expanded chemoprophylaxis can be used as an interim measure to temporarily reduce meningococcal carriage and transmission before protection from vaccination can be achieved (see section on expanded chemoprophylaxis).

Efforts should be made to educate communities, physicians and other health-care personnel about meningococcal disease to promote early care-seeking behaviors and recognition of cases. In general, restricting travel, closing schools or cancelling sporting or social events are not recommended.

### Risk Communication

Immediately contact administrators of schools or other institutions where a case of meningococcal disease has occurred. Recommend that affected schools and institutions rapidly communicate (phone trees, e-mail) with their populations and help guide messaging. CDPH can provide assistance with messaging and letters.

Information communicated should include:

- Notification about the case (obtain consent if the name of the case is to be released).
- Reassurance that the risk of another case is remote.
- Signs and symptoms of meningococcal disease and instructions to seek care promptly if they occur.
- Persons recommended to receive chemoprophylaxis will be notified by public health authorities.
- Serogroup specific vaccination recommendations.

### *N. meningitidis* Infection in a Non-sterile Site

**Conjunctivitis:** Because invasive disease has occurred among close contacts of meningococcal conjunctivitis cases, CDPH considers it reasonable to manage close contacts of meningococcal conjunctivitis cases in the same manner as close contacts of invasive disease cases. This is not a CDC recommendation. If the meningococcal conjunctivitis case has not been treated with ceftriaxone or cefotaxime, the case should also receive chemoprophylaxis.

**Urethritis:** *N. meningitidis* can also be a cause of urethritis. It is recommended that *N. meningitidis* urethritis be treated as *N. gonorrhoeae* urethritis would be treated (a single 250-mg dose of intramuscular ceftriaxone plus a single 1-g oral dose of azithromycin).

**CDC recommends** that sex partners of patients with *N. meningitidis* urethritis be treated as they would be for *N. gonorrhoeae* exposure. See: <https://www.cdc.gov/mmwr/volumes/65/wr/mm6521a5.htm>

## Reporting

All suspected, probable and confirmed cases of meningococcal disease should be immediately reported by phone to CDPH. All meningococcal disease cases should also be reported to CDPH via CalREDIE or [CDPH form 8469](#), available at: <https://www.cdph.ca.gov/CDPH%20Document%20Library/ControlledForms/cdph8469.pdf>

If 1 suspected, probable or confirmed case is identified in a high school or college student, or 2 or more cases are identified in the same institution or social network, or if other unusual situations are identified, please contact the CDPH Immunization Branch at (510) 620-3737 for additional guidance.

## Recommended chemoprophylaxis regimens\*

| Age                                | Dose   | Duration    | Efficacy | Cautions   |
|------------------------------------|--|-------------|----------|--|
| <b>Rifampin<sup>a</sup></b>        |  |             |          |  |
| <1 month                           | 5 mg/kg, every 12 h, po                      | 2 days      |          | Discussion with an expert for infants <1 month of age.   |
| ≥1 month                           | 15-20 mg/kg (maximum 600 mg), every 12 h, po | 2 days      | 90–95%   | Can interfere with efficacy of oral contraceptives and some seizure and anticoagulant medications; can stain soft contact lenses.          |
| <b>Ceftriaxone</b>                 |  |             |          |  |
| <15 years                          | 125 mg, intramuscularly                      | Single dose | 90–95%   | To decrease pain at injection site, dilute with 1% lidocaine.  |
| ≥15 years                          | 250 mg, intramuscularly                      | Single dose | 90–95%   | To decrease pain at injection site, dilute with 1% lidocaine.  |
| <b>Ciprofloxacin<sup>a,b</sup></b> |  |             |          |  |
| ≥1 month                           | 20 mg/kg (maximum 500 mg), po                | Single dose | 90–95%   |  |
| <b>Azithromycin</b>                | 10 mg/kg (maximum 500 mg), po                | Single dose | 90%      | Not recommended routinely; equivalent to rifampin for eradication of <i>N. meningitidis</i> from nasopharynx in one study of young adults. |

\***Penicillin** is often appropriate as treatment, but is not appropriate for chemoprophylaxis.

<sup>a</sup> Not recommended for use in pregnant women.

<sup>b</sup> Use only if fluoroquinolone-resistant strains of *N. meningitidis* have not been identified in the community. As of July 2020, only a single case of fluoroquinolone-resistant *N. meningitidis* has been identified in California, in 2019. If the case's isolate is known to be resistant to fluoroquinolones, or if there are resistant strains circulating in the community, rifampin or azithromycin may be appropriate choices.

From AAP 2018-2021 Red Book.